Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. (Q37398972)
Jump to navigation
Jump to search
scientific article published on 26 July 2016
Language | Label | Description | Also known as |
---|---|---|---|
English | Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. |
scientific article published on 26 July 2016 |
Statements
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality (English)
Mark Woodward
Kazem Rahimi
Mike Kirby
Geoff Hackett
Andrew W Trafford
1 reference
1 reference